What is HC Wainwright’s Estimate for FTH Q2 Earnings?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) – Stock analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Sensei Biotherapeutics in a report issued on Monday, June 22nd. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.63) per share for the quarter. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($16.61) EPS and FY2027 earnings at ($3.72) EPS.

Several other research firms also recently issued reports on FTH. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Sensei Biotherapeutics Trading Up 3.5%

Shares of FTH stock opened at $24.00 on Wednesday. The stock has a market cap of $32.21 million, a PE ratio of -0.17 and a beta of -0.25. Sensei Biotherapeutics has a 12 month low of $6.32 and a 12 month high of $36.76.

Key Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: HC Wainwright initiated/expanded coverage on Sensei Biotherapeutics with a Buy rating and $60 price target, implying substantial upside from current levels. Benzinga
• Neutral Sentiment: The firm released detailed earnings estimates for 2026 through 2030, forecasting ongoing losses in the near term and later-period EPS projections that may help shape investor expectations. Benzinga

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.